Bayer thought it might be able to expand Xofigo in prostate cancer by testing it with Johnson & Johnson’s Zytiga. But that plan has hit a snag. More: Bayer pulls veil back on Xofigo-Zytiga combo study after deaths, fractures crop
read moreIt’s not a great time for Sanofi and its vaccines business. Days after raising a red flag on its dengue shot Dengvaxia, the company gave up on its C. diff vaccine candidate, a product that could have been a $500
read moreMylan and Biocon’s Ogivri is the first biosimilar of Herceptin to win US approval, for certain breast cancer and metastatic stomach cancers. More: US approves first Herceptin biosimilar Source: News
read moreSanofi has pulled the plug on its experimental Clostridium difficile vaccine after an interim analysis of a late-stage trial concluded that key targets were unlikely to be met. More: Sanofi ends development of Clostridium difficile vaccine Source: News
read moreDecember has kicked off with NHS hospital performance against the four hour A&E target standing at just 82.45 percent – 12.55 percentage points lower than the 95 percent standard, reports the Royal College of Emergency Medicine (RCEM). More: NHS A&E
read moreThe veteran bloodthinner heparin has been found in a small UK trial to help improve breathing when inhaled by patients with chronic obstructive pulmonary disease (COPD). More: Inhaled heparin shows potential in lung disease Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals